Abstract

White matter alterations are present in the majority of patients with Alzheimer's disease type dementia. However, the spatiotemporal pattern of white matter changes preceding dementia symptoms in Alzheimer's disease remains unclear, largely due to the inherent diagnostic uncertainty in the preclinical phase and increased risk of confounding age-related vascular disease and stroke in late-onset Alzheimer's disease. In early-onset autosomal-dominantly inherited Alzheimer's disease, participants are destined to develop dementia, which provides the opportunity to assess brain changes years before the onset of symptoms, and in the absence of ageing-related vascular disease. Here, we assessed mean diffusivity alterations in the white matter in 64 mutation carriers compared to 45 non-carrier family non-carriers. Using tract-based spatial statistics, we mapped the interaction of mutation status by estimated years from symptom onset on mean diffusivity. For major atlas-derived fibre tracts, we determined the earliest time point at which abnormal mean diffusivity changes in the mutation carriers were detectable. Lastly, we assessed the association between mean diffusivity and cerebrospinal fluid biomarkers of amyloid, tau, phosphorylated-tau, and soluble TREM2, i.e. a marker of microglia activity. Results showed a significant interaction of mutations status by estimated years from symptom onset, i.e. a stronger increase of mean diffusivity, within the posterior parietal and medial frontal white matter in mutation carriers compared with non-carriers. The earliest increase of mean diffusivity was observed in the forceps major, forceps minor and long projecting fibres-many connecting default mode network regions-between 5 to 10 years before estimated symptom onset. Higher mean diffusivity in fibre tracts was associated with lower grey matter volume in the tracts' projection zones. Global mean diffusivity was correlated with lower cerebrospinal fluid levels of amyloid-β1-42 but higher levels of tau, phosphorylated-tau and soluble TREM2. Together, these results suggest that regionally selective white matter degeneration occurs years before the estimated symptom onset. Such white matter alterations are associated with primary Alzheimer's disease pathology and microglia activity in the brain.

Highlights

  • In Alzheimer’s disease, white matter degeneration is a frequent structural brain change apart from grey matter atrophy (Brun and Englund, 1986)

  • We found significant interactions of EYO by mutation status on mean diffusivity predominantly in posterior parietal and medial frontal regions of the white matter (Fig. 1, peak coordinates in Table 2), indicating a faster increase of mean diffusivity in carriers compared to non-carriers

  • The major finding of the current study was the region-specific increase in mean diffusivity that emerged about 10 years before the estimated onset of dementia symptoms

Read more

Summary

Introduction

In Alzheimer’s disease, white matter degeneration is a frequent structural brain change apart from grey matter atrophy (Brun and Englund, 1986). Post-mortem studies showed loss of myelin, axonal degeneration and gliosis in the brains from patients with Alzheimer’s disease (Brun and Englund, 1986). Such white matter alterations cannot be fully accounted for as degenerative processes secondary to grey matter damage (Brun and Englund, 1986; Englund, 1998; Agosta et al, 2011), but may stem from vascular amyloid deposition and microvascular damage (Weller et al, 2009). White matter alterations, possibly stemming from cerebrovascular disease, may add to the effects of amyloid deposition on neurodegeneration and cognition in ageing and Alzheimer’s disease

Objectives
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.